Abeona slumps after FDA declines approval for its skin disorder treatment

Abeona Therapeutics

22/04/2024 22:08

** Shares of Abeona Therapeutics  ABEO.O  fall nearly 53% to
$3.48 after hours
    ** U.S. FDA declines to approve Abeona's treatment for
recessive dystrophic epidermolysis bullosa, a rare skin
blistering condition
    ** FDA requests certain additional information to satisfy a
critical part of any pharmaceutical product application
    ** Co says FDA did not identify "any deficiencies related to
the clinical efficacy or clinical safety data" and has not
requested any new clinical trials or clinical data to support
the approval
    ** ABEO anticipates submitting the required information in
3Q 2024 
    ** Up to last close, stock up 46.91% YTD

 (Reporting by Juby Babu)
 ((Juby.Babu@thomsonreuters.com;))